Syngene International is currently trading at Rs. 387.15, up by 16.25 points or 4.38% from its previous closing of Rs. 370.90 on the BSE.
The scrip opened at Rs. 386.55 and has touched a high and low of Rs. 390.00 and Rs. 384.00 respectively. So far 4579 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 690.00 on 03-Jun-2020 and a 52 week low of Rs. 201.65 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 390.00 and Rs. 340.50 respectively. The current market cap of the company is Rs. 14836.00 crore.
The promoters holding in the company stood at 70.69%, while Institutions and Non-Institutions held 22.71% and 6.61% respectively.
Syngene International has entered into collaboration with HiMedia Laboratories, a bioscience company with expertise in media manufacturing and diagnostics for over 45 years, to manufacture and distribute its ELISA kits. HiMedia will manufacture the kits at its facility in Mumbai and distribute it across India.
Syngene has indigenously developed an anti-COV-2 IgG ELISA (Enzyme-Linked Immunosorbent Assay) at its research facility in Bengaluru. This advanced highly reliable test identifies the presence of SARS-COV-2 antibodies in blood samples and confirms if a patient has been exposed to the coronavirus. It has a capacity to test samples together in a single run and generates results within 3 hours.
Syngene International is India’s largest Contract Research Services Organization providing integrated discovery and development services for novel molecules across multiple platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides.
